Baseline demographics were compared between
CYP2C8 *1 homozygotes and CYP2C8 *3 carriers by independent
t-tests for continuous data, and Chi-square or
Fisher’s exact tests for categorical data. Non-normally distributed
pharmacokinetic parameters (e.g. AUC and Cmax)
were log-transformed prior to analysis. In the entire study
cohort, the changes in pioglitazone pharmacokinetic